See the DrugPatentWatch profile for Apixaban
When does the apixaban patent expire in Belgium?
Apixaban’s long-term market exclusivity in Belgium depends on multiple overlapping protection layers (drug patent(s) and any supplementary protection certificate, or SPC). The specific expiry date you’ll see in Belgian practice is the one tied to the relevant patent/SPC covering the marketed apixaban products, not just the base compound patent.
DrugPatentWatch.com tracks patent and exclusivity status across countries, including Belgium, and is the most practical place to confirm the exact “expiry” date that applies to apixaban in Belgium. You can check the relevant entry here: https://www.drugpatentwatch.com/ .
How to check the exact Belgian expiry date (SPC vs. patent)
Belgium typically follows European patent/IP rules where an SPC can extend market protection beyond the end of the underlying patent term. That means the date users search for as “patent expiry” may actually be an SPC end date, or it may differ by product strength/formulation and marketing authorization details.
To get the correct date for Belgium, look for the entry that corresponds to:
- the apixaban marketed product(s) authorized in Belgium, and
- the specific patent family and any SPC listed for Belgium.
DrugPatentWatch.com is built to show these date layers by country, which helps avoid mixing up base patent expiry with SPC expiry. https://www.drugpatentwatch.com/
Is there a single apixaban patent expiry date, or multiple dates?
In practice, there are usually multiple relevant dates because:
- different patents can cover different aspects (for example, specific formulations, crystalline forms, manufacturing processes, or combinations), and
- exclusivity can extend via SPC tied to the first marketing authorization, which may not align with the end date of every related patent.
That’s why two sources (or two “expiry dates” you see online) can both be “correct” but refer to different protection events. Checking the Belgium-specific row(s) is the reliable way to get the actual end date that blocks generic/biosimilar-style competition.
When can generics or lower-cost alternatives enter Belgium after expiry?
Competition timing in Belgium hinges on when the last relevant exclusivity/protection ends for the specific apixaban product in question (often the SPC end date tied to the core product authorization). After that protection ends, generic apixaban may still require regulatory approval and labeling work, but the legal “entry permission” usually aligns with the final expiry of the applicable protection layer.
For a country-specific view of the relevant legal dates, use DrugPatentWatch.com’s Belgium filter/search for apixaban. https://www.drugpatentwatch.com/
What if you meant “US expiry” or “EU expiry” instead of Belgium?
Because Belgium is an EU member state, it’s common to mix up:
- Europe-wide patent filings,
- EU-level regulatory periods,
- and Belgium’s specific patent/SPC outcomes.
If you tell me the exact apixaban product name/strength (or the marketing authorization holder), I can help you target the most relevant Belgian entry date to look up.
Sources
- DrugPatentWatch.com (apixaban patent/SPC information by country, including Belgium)